Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Under valuation model assumptions realized through 12/31/28, the stock is modeled using: Revenue growth (CAGR): 15.9% Operating Margins: 4.5% Exit P/E Multiple: 24.7x Based on these inputs, the model estimates a target price of $33, implying 17.7% total upside from the current share price of $28 and a 6.3% annualized return over the next 2.7 years
Nicotinamide N-Methyltransferase NNMT is a cytosolic methyltransferase that uses S-adenosyl-L-methionine to methylate nicotinamide
Can BPC-157 or TB-500 heal tendon injuries
[18] LanCL1 has been identified as a binding and functional mediator of LAT8881 activity in neuropathic-pain models, but its role in adipocyte or whole-body metabolic effects remains unresolved
US$ 22.68
US$ 29.26
US$ 29.50
US$ 20.01
US$ 25.52
US$ 29.27
US$ 25.69
US$ 26.91
US$ 26.83
